APM
RCUS icon

Avidity Partners Management’s Arcus Biosciences RCUS Stock Holding History

Avidity Partners Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-912,000
Closed -$28.8M – 95
2022
Q1 		$28.8M Buy
+912,000
New +$30.6M 0.6% 44
2020
Q3 		– Sell
-589,000
Closed -$14.6M – 82
2020
Q2 		$14.6M Buy
+589,000
New +$15.9M 0.93% 41

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Avidity Partners Management's RCUS Position: Q2 2022 in Review

Avidity Partners Management sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 912,000 shares — an estimated $28.8M sold.

Avidity Partners Management first reported a position in RCUS in Q2 2020 and held it in 2 quarters. The position peaked at $28.8M in Q1 2022. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

  • Avidity Partners Management reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
  • Avidity Partners Management sold 912,000 Arcus Biosciences shares in Q2 2022, an estimated $28.8M.
  • Avidity Partners Management first reported a position in Arcus Biosciences in Q2 2020 and held it in 2 quarters.
  • Avidity Partners Management's Arcus Biosciences position peaked at $28.8M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.